Natural Compounds Show Promise in Treating Multiple Myeloma, But Pharmacokinetic Challenges Persist

Strategic Insights -

Investigators at Lucile Packard Children's Hospital Stanford have published a review exploring the inhibitory effects of natural compounds on multiple myeloma cells. The research highlights the potential of these compounds to target cancer cells, but also emphasizes the need for improved delivery methods to enhance their therapeutic efficacy.

Key Takeaways:

  • Natural compounds such as 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO), caffeic acid phenethyl ester (CAPE), and xanthohumol (XN) have shown potent anti-proliferative, pro-apoptotic, and anti-inflammatory properties in multiple myeloma cells.
  • Nanoparticle (NP) carriers have been engineered to improve the bioavailability and targeted delivery of these natural compounds, enhancing their cytotoxicity against multiple myeloma cells.
  • For example, CDDO and its derivatives encapsulated in NPs have demonstrated increased intracellular accumulation and improved inhibition of NF-kB activity.
  • NP formulations of CAPE, XN, and resveratrol (RSV) have also enhanced anti-MM effects through improved stability and sustained drug release.
  • Curcumin (CUR), known for its poor water solubility, has seen its therapeutic potential augmented through NP delivery systems, enabling higher drug concentrations at tumor sites.
  • Other compounds such as 3,4,5-trihydroxybenzoic acid (gallic acid; GA) and evodiamine (EVO) have also benefited from NP-based enhancement, exhibiting improved bioavailability and selective targeting of multiple myeloma cells.

Statistics:

  • The review highlights the potential of NP carriers in overcoming the pharmacokinetic limitations of natural compounds, offering new avenues for more effective multiple myeloma therapies. (Frontiers in Pharmacology, 2025, 16).
  • The research was conducted by a team of investigators led by Erica Wong from the Department of Inpatient Pharmacy at Lucile Packard Children's Hospital, Palo Alto, CA, United States.
  • Additional authors on the research include Anna Staskiewicz, Joshua Pruner, Jean Lee, Michael Tucker, Barkley Smith, Lanerica Rogers, Ganiat Asuni, and Xinyu Wang.

Sources:

  • Frontiers in Pharmacology, 2025,16 (Frontiers in Pharmacology - http://journal.frontiersin.org/journal/pharmacology)
  • The publisher for Frontiers in Pharmacology is Frontiers Media S.A. (https://www.frontiersin.org)
  • doi.org/10.3389/fphar.2025.1589090 (https://doi.org/10.3389/fphar.2025.1589090)